A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Trial Profile

A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs RV 001 (Primary)
  • Indications Prostate cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors RhoVac
  • Most Recent Events

    • 19 Mar 2018 Data related to vaccine-mediated immune response was reported in December 2017, according to a RhoVac media release
    • 19 Mar 2018 According to a RhoVac media release, the treatment phase was completed for the first patient in mid-November 2017. All patients have finished treatment and in March 2018 the final blood samples will be taken for immunological monitoring. The final result will be reported in the second quarter of 2018.
    • 02 Jul 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top